GLAND PHARMA Latest Share Price (GLAND)
TODAY IN ONE LINE
GLAND slipped 0.8% on light volume, in line with Nifty's -0.3% move.
With a market cap of ₹48,333.19 Cr., it trades at a P/E of 42.78. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
GLAND PHARMA flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 96.4% YoY
- ●High Capital EfficiencyROCE of 17.2% indicating pricing power
- ●Healthy Operating MarginsOPM is structurally strong at 38.8%
- ●High Promoter HoldingPromoters hold 51.8% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●FII AccumulationFII holding increased by 1.44% QoQ
- ●Promoter BuyingPromoters increased holdings by 51.77% QoQ
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Sales ContractionQuarterly sales dropped 28.5% YoY
Latest GLAND PHARMA News
What changed recently?
Recent events, corporate actions, and announcements.
GLAND PHARMA valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for GLAND PHARMA, framed against the sector median so the premium or discount is obvious at a glance.
GLAND PHARMA trades at a P/E of 42.78× and P/B of 4.66×, against the Healthcare sector median P/E of 41.12×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
GLAND PHARMA technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for GLAND PHARMA — derived from the latest tape, not yesterday's close.
GLAND PHARMA last traded at ₹2,922.3 with an intraday range of ₹2,882–₹2,950.1 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹2922.30| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 3090.47 | +168.17 | +5.75% |
| R3 | 3022.37 | +100.07 | +3.42% |
| R2 | 2986.23 | +63.93 | +2.19% |
| R1 | 2954.27 | +31.97 | +1.09% |
| PIVOT | 2918.13 | -4.17 | -0.14% |
| CURRENT | 2922.30 | — | — |
| S1 | 2886.17 | -36.13 | -1.24% |
| S2 | 2850.03 | -72.27 | -2.47% |
| S3 | 2818.07 | -104.23 | -3.57% |
| S4 | 2749.97 | -172.33 | -5.90% |
GLAND is trading Above CPR, indicating Bullishness
CPR is Narrower, suggesting likely for trending moves
Day's range: ₹2886–₹2940
Trading Inside opening range
GLAND PHARMA financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for GLAND PHARMA — consolidated or standalone — with margins, YoY growth and key ratios inline.
GLAND PHARMA reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹48,333.19 Cr. and reported EPS of ₹22.09.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 5,617 | 6,431 ▲ 14.5% |
| Sales Growth YoY %Derived | -0.85% | 14.50% |
| Other Income | 214 | 316 ▲ 48.1% |
| Total Income | 5,830 | 6,747 ▲ 15.7% |
| 2,090 | 2,243 ▲ 7.3% | |
| Gross ProfitDerived | 3,526 | 4,188 ▲ 18.8% |
| Gross Margin %Derived | 62.78% | 65.12% |
| 2,257 | 2,558 ▲ 13.3% | |
| EBITDA (Operating Profit)Derived | 1,269 | 1,630 ▲ 28.4% |
| OPM %Derived | 22.59% | 25.34% |
| 420 | 433 ▲ 3.0% | |
| Profit Before Tax (PBT) | 1,063 | 1,465 ▲ 37.8% |
| 364 | 437 ▲ 20.1% | |
| Effective Tax %Derived | 34.27% | 29.86% |
| Total Profit for Period | 699 | 1,027 ▲ 47.1% |
| Net Profit (Owner's PAT)Derived | 699 | 1,027 ▲ 47.1% |
| Net Profit Margin %Derived | 12.44% | 15.98% |
| PAT Growth YoY %Derived | -9.57% | 47.07% |
| Earnings Per Share (EPS ₹) | 42.40 | 62.35 ▲ 47.1% |
| Diluted Shares Outstanding (Cr) | 16 | 16 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 55 | 431 ▲ 678.1% |
| Total Expenses (incl. D&A & Interest) | 4,767 | 5,282 ▲ 10.8% |
| Material Cost % of RevenueDerived | 35.12% | 34.83% |
| Employee Cost % of RevenueDerived | 24.95% | 25.33% |
| Other Cost % of RevenueDerived | 15.23% | 14.45% |
| Interest Coverage (x)Derived | 21.22x | 36.24x |
| Period | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | 3,463 | 4,401 ▲ 27.1% | 3,625 ▼ 17.6% | 5,665 ▲ 56.3% | 5,617 ▼ 0.9% | 6,431 ▲ 14.5% | |
| Sales Growth YoY %Derived | — | 27.08% | -17.64% | 56.29% | -0.85% | 14.50% | |
| Other Income | 135 | 224 ▲ 66.2% | 240 ▲ 7.4% | 170 ▼ 29.2% | 214 ▲ 25.5% | 316 ▲ 48.1% | |
| Total Income | 3,598 | 4,625 ▲ 28.5% | 3,865 ▼ 16.4% | 5,835 ▲ 51.0% | 5,830 ▼ 0.1% | 6,747 ▲ 15.7% | |
1,492 | 2,109 ▲ 41.4% | 1,685 ▼ 20.1% | 2,173 ▲ 28.9% | 2,090 ▼ 3.8% | 2,243 ▲ 7.3% | ||
| Gross ProfitDerived | 1,971 | 2,291 ▲ 16.3% | 1,939 ▼ 15.4% | 3,492 ▲ 80.1% | 3,526 ▲ 1.0% | 4,188 ▲ 18.8% | |
| Gross Margin %Derived | 56.92% | 52.07% | 53.50% | 61.64% | 62.78% | 65.12% | |
669 | 781 ▲ 16.8% | 914 ▲ 17.0% | 2,159 ▲ 136.1% | 2,257 ▲ 4.6% | 2,558 ▲ 13.3% | ||
| EBITDA (Operating Profit)Derived | 1,302 | 1,510 ▲ 16.0% | 1,025 ▼ 32.1% | 1,333 ▲ 30.1% | 1,269 ▼ 4.8% | 1,630 ▲ 28.4% | |
| OPM %Derived | 37.61% | 34.32% | 28.27% | 23.53% | 22.59% | 25.34% | |
102 | 116 ▲ 13.1% | 98 ▼ 15.4% | 371 ▲ 279.4% | 420 ▲ 13.2% | 433 ▲ 3.0% | ||
| Profit Before Tax (PBT) | 1,335 | 1,619 ▲ 21.3% | 1,055 ▼ 34.8% | 1,133 ▲ 7.4% | 1,063 ▼ 6.2% | 1,465 ▲ 37.8% | |
338 | 407 ▲ 20.4% | 274 ▼ 32.8% | 360 ▲ 31.6% | 364 ▲ 1.1% | 437 ▲ 20.1% | ||
| Effective Tax %Derived | 25.31% | 25.14% | 25.94% | 31.79% | 34.27% | 29.86% | |
| Total Profit for Period | 997 | 1,212 ▲ 21.5% | 781 ▼ 35.5% | 772 ▼ 1.1% | 699 ▼ 9.6% | 1,027 ▲ 47.1% | |
| Net Profit (Owner's PAT)Derived | 997 | 1,212 ▲ 21.5% | 781 ▼ 35.5% | 772 ▼ 1.1% | 699 ▼ 9.6% | 1,027 ▲ 47.1% | |
| Net Profit Margin %Derived | 28.79% | 27.53% | 21.55% | 13.64% | 12.44% | 15.98% | |
| PAT Growth YoY %Derived | — | 21.54% | -35.54% | -1.10% | -9.57% | 47.07% | |
| Earnings Per Share (EPS ₹) | 60.94 | 73.75 ▲ 21.0% | 47.42 ▼ 35.7% | 46.90 ▼ 1.1% | 42.40 ▼ 9.6% | 62.35 ▲ 47.1% | |
| Diluted Shares Outstanding (Cr) | 16 | 16 ▲ 0.4% | 16 ▲ 0.2% | 16 ▲ 0.0% | 16 ▲ 0.0% | 16 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | -1 | -0 ▲ 47.5% | -1 ▼ 214.0% | -8 ▼ 446.9% | 55 ▲ 804.2% | 431 ▲ 678.1% | |
| Total Expenses (incl. D&A & Interest) | 2,263 | 3,006 ▲ 32.8% | 2,810 ▼ 6.5% | 4,702 ▲ 67.3% | 4,767 ▲ 1.4% | 5,282 ▲ 10.8% | |
| Material Cost % of RevenueDerived | 50.51% | 46.51% | 47.36% | 35.70% | 35.12% | 34.83% | |
| Employee Cost % of RevenueDerived | 8.99% | 7.69% | 11.13% | 22.19% | 24.95% | 25.33% | |
| Other Cost % of RevenueDerived | 10.32% | 10.06% | 14.10% | 15.92% | 15.23% | 14.45% | |
| Interest Coverage (x)Derived | 352.81x | 267.05x | 117.90x | 37.73x | 21.22x | 36.24x |
GLAND PHARMA segment analysis : revenue and profit mix.
Disclosed business segments at GLAND PHARMA with their share of revenue and profit, switchable between consolidated and standalone reporting.
GLAND PHARMA discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for GLAND PHARMA.
Our AI distills the core fundamental drivers supporting GLAND PHARMA, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
GLAND PHARMA's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Latest quarterly EPS grew 96.6% YoY, reflecting exceptional earnings acceleration momentum.
TTM revenue growth of 22.3% significantly outpaces most pharmaceutical sector peers.
Operating margin of 18.75% demonstrates robust profitability and strong pricing power.
Debt-to-equity ratio near zero ensures fortress-like financial flexibility and stability.
Promoter holding of 51.77% signals strong management commitment and aligned governance.
Key Risks.
P/E ratio of 39.68x is elevated, suggesting premium valuation and high growth expectations.
Dividend yield of 0.68% is low, unattractive for income-focused investors seeking returns.
ROE of 9.92% lags peer benchmarks, indicating moderate capital efficiency and returns.
ROCE of 14.51% below sector averages, limiting reinvestment returns on deployed capital.
FII holdings eased from 9.41% to 6.90%, signaling foreign investor caution and concern.
Flip Conditions.
Valuation risk. a P/E above 56 (~1.4× the sector multiple of 41.1) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.34%.
GLAND PHARMA peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — GLAND PHARMA is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
GLAND PHARMA chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for GLAND PHARMA — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
GLAND PHARMA delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for GLAND PHARMA over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in GLAND PHARMA stood at 52.7% of traded volume, against a 20-day average of 52.6%.
GLAND PHARMA announcements: results, concalls, ratings, M&A.
Filings GLAND PHARMA sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
GLAND PHARMA files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 185 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Gland Pharma Limited has informed the Exchange about Schedule of meet
Analysts/Institutional Investor Meet/Con. Call Updates
Gland Pharma Limited has informed the Exchange about Schedule of meet
Analysts/Institutional Investor Meet/Con. Call Updates
Gland Pharma Limited has informed the Exchange about Schedule of meet
General Updates
Gland Pharma Limited has informed the Exchange about General Updates
Analysts/Institutional Investor Meet/Con. Call Updates
Gland Pharma Limited has informed the Exchange about Schedule of meet
Investor decks & rating reports.
GLAND PHARMA dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue GLAND PHARMA has declared, sequenced by announce and record date.
GLAND PHARMA corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
GLAND PHARMA insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in GLAND PHARMA as reported to SEBI — buying and selling signals from the people who know the business best.
GLAND PHARMA insider activity below tracks 1 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| S SRINIVASA RAO | Insider | 26 Feb 2025 | buy | +2.8 K | ₹15.18 L | ₹542.00 |
About GLAND PHARMA: business, sector, key facts.
What GLAND PHARMA does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
GLAND PHARMA operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: GLAND, BSE: 543245.
Gland Pharma Limited is a prominent pharmaceutical company specializing in the manufacturing and sale of injectable formulations. Its global reach extends to India, the United States, Europe, Canada, Australia, New Zealand, and other international markets, showcasing a significant international presence and distribution network. The company's business model centers around providing a diverse range of injectable medications to meet various therapeutic needs.
A core aspect of Gland Pharma's operations involves the research and development of active pharmaceutical ingredients (APIs). This includes the complex synthesis of molecules such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. This in-house capability allows for greater control over the quality and supply chain of their products, and signifies a commitment to innovation within the pharmaceutical sector.
The company's product portfolio caters to a wide spectrum of therapeutic areas. This includes anti-malarial, anti-infectives, anti-neoplastic, blood-related, cardiac, gastrointestinal, gynecological, hormonal, neuro/CNS, ophthalmological/otological, pain and analgesic, respiratory medications, and vitamins, minerals, and nutrient supplements. The breadth of therapeutic categories serviced indicates a commitment to addressing a variety of patient needs and healthcare challenges.
Beyond manufacturing and sales, Gland Pharma also offers contract development services. This suggests that the company not only produces its own injectable medications but also provides research and development support to other pharmaceutical entities. This additional revenue stream diversifies the company’s income and expands its role within the industry ecosystem.
Established in 1978 and headquartered in Hyderabad, India, Gland Pharma operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd. This affiliation with a larger parent company provides financial backing and potentially access to broader resources and markets, contributing to the company's ongoing success and expansion.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Other overvalued NSE stocksScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about GLAND PHARMA (GLAND).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of GLAND PHARMA (GLAND)?
The current share price of GLAND PHARMA (GLAND) is ₹2,922.30. Today, the stock has declined by ₹24.60 (0.83%), trading in a range of ₹2,882.00 to ₹2,950.10. The stock opened at ₹2,940.00 with a trading volume of 3,89,004 shares.
02Is GLAND PHARMA stock a good investment for long-term?
GLAND PHARMA can be considered for long-term investment based on several factors. The company has a market capitalization of ₹48,333.19 Cr., P/E ratio of 42.78, ROE of 12.02%, and ROCE of 17.2%. The dividend yield stands at 0.68%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of GLAND PHARMA stock?
The 52-week high price of GLAND PHARMA (GLAND) is ₹3,042.00, while the 52-week low is ₹1,573.60. Currently trading at ₹2,922.30, the stock is 85.71% above its 52-week low and 3.93% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy GLAND PHARMA stock at the current price?
Whether to buy GLAND PHARMA stock at ₹2,922.30 depends on multiple factors. The stock is currently trading with a P/E ratio of 42.78 and P/B ratio of 4.66. Today's performance shows a loss of 0.83%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of GLAND PHARMA and when is the next dividend?
GLAND PHARMA offers a dividend yield of 0.68%, which means for every ₹100 invested at the current price of ₹2,922.30, you can expect to receive approximately ₹0.68 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of GLAND PHARMA?
GLAND PHARMA's key financial metrics include: P/E Ratio: 42.78, P/B Ratio: 4.66, ROE: 12.02%, ROCE: 17.2%, Dividend Yield: 0.68%, EPS: ₹22.09, Book Value: ₹627.91, and Debt-to-Equity: 0. The company's market cap stands at ₹48,333.19 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is GLAND PHARMA stock performing today in the market?
GLAND PHARMA stock opened at ₹2,940.00 and is currently trading at ₹2,922.30, showing a decline of ₹24.60 (0.83%). The intraday high is ₹2,950.10 and low is ₹2,882.00. The trading volume stands at 3,89,004 shares, indicating moderate market participation today.
08What is the P/E ratio of GLAND PHARMA and what does it indicate?
GLAND PHARMA has a Price-to-Earnings (P/E) ratio of 42.78, which means investors are willing to pay 42.78 for every ₹1 of earnings. With an EPS of ₹22.09, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about GLAND PHARMA (GLAND) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.